Winter Meeting 2011 - The Pathological Society of Great Britain ...

More documents

Recommendations

Info

Detailed Programme – Thursday 6 January 2011 Presenter = P · Abstract numbers are shown in bold and square brackets eg [S123] mirrored by alterations in FAK although ILK expression did not seem to be perturbed. Information about Cten regulation is sparse but we have recently shown that Cten is downstream of Kras in colon cancer. Since around 80% of pancreatic cancers possess a Kras mutation, we hypothesised that Kras may regulate Cten. Knockdown of Kras resulted in down-regulation of Cten and inhibition of cell motility (p
Detailed Programme – Thursday 6 January 2011 Presenter = P · Abstract numbers are shown in bold and square brackets eg [S123] 16.45–17.00 [PL6] K-ras Mutation is a Negative Prognostic Marker, and Does Not Preclude Benefit From 5-FU in Stage II/III Colorectal Cancer P K Southward 1 ; G Hutchins 1 ; K Handley 2 ; L Magill 2 ; C Beaumont 1 ; J Stalhschmidt 3 ; S Richman 1 ; P Chambers 1 ; M Seymour 4 ; D Kerr 5 ; R Gray 2 ; P Quirke 1 1 Leeds Institute of Molecular Medicine, Leeds, United Kingdom; 2 Birmingham Clinical Trials Unit, Birmingham, United Kingdom; 3 Histopathology and Molecular Pathology, Leeds, United Kingdom; 4 CRUK Cancer Centre, Leeds, United Kingdom; 5 Sidra Medical and Research Centre, Doha, Qatar There is currently uncertainty whether the efficacy of 5-FU adjuvant therapy in stage II colorectal cancer is sufficient to justify the cost and toxicity. Tumour markers that could distinguish patients who will benefit from adjuvant chemotherapy from those that won’t, or that were strongly associated with disease prognosis, are desirable both to save money and to avoid treating patients who would derive little or no benefit from chemotherapy. Mutations of the Kirsten-ras gene occur in 30–40% of sporadic colorectal cancers and are established as clinically useful predictors of lack of response to EGF receptor targeted treatment in stage IV disease. We assessed the Kirsten-ras gene as a predictor of response to chemotherapy and risk of recurrence in patients with stage II/III colorectal cancer randomised between fluorouracil/folinic acid (FUFA) chemotherapy and control in the Quasar clinical trial. K-ras mutation status was assessed by pyrosequencing for 1583 tumours and was then correlated to prognosis and treatment benefit from FUFA therapy. The risk of recurrence for K-ras mutant tumours was significantly higher than that of wildtype: 28% vs 21% (RR=1.40, 95% CI 1.13-1.74). The proportional increase in risk of recurrence was larger in rectal cancer and in men but similar in the presence and absence of chemotherapy. K-ras did not predict response to FUFA treatment K-ras mutation is a useful predictor of recurrence risk in stage II/III colorectal cancer. The greater prognostic value in rectal cancer and men needs independent confirmation. 17.00–17.15 [PL7] Activating Autophagocytosis Decreases Fat Within the Liver P A Levene 1 ; H Kudo 1 ; M Thursz 1 ; QM Anstee 2 ; RD Goldin 1 Imperial College Faculty of Medicine at St Mary’s Hospital, London, United Kingdom; The Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom Background: Autophagy is the degradation of intracellular components by the lysosome system. Macroautophagy is when content is sequestered in a double membrane structure which fuses with a lysosome and subsequently the contents are degraded. Recently it has been suggested that macroautophagy plays a role in fat metabolism within the liver. Our aim was to activate autophagocytosis in liver cells and assess the fat levels and amount of autophagocytosis. Methods: HUH7 cells, a liver differentiated cell line, were grown in normal or high fat medium with and without rapamcyin, an autophagocytosis activator for 24 hours. The cells were stained with Oil Red-O (ORO) and the percentage fat calculated using digital image analysis (DIA). Triglyceride levels within the cells were measured biochemically as a true reflection of cell lipid content. Autophagocytosis was measured in the cells using co-localistation of LAMP1 (a lysosomal marker) and BODIPY (a neutral lipid marker) by confocal immunofluorescence microscopy. Results: ORO staining identified significantly more fat in the cells grown in oleate medium compared to normal medium (p
Page 1 and 2: Pathological Society Understanding
Page 3 and 4: Programme acknowledgements This Pro
Page 5 and 6: Programme Quick Reference Tables Fo
Page 7 and 8: Scientific Session Information PLEN
Page 9 and 10: General Arrangements / Future Meeti
Page 11 and 12: Foyer 08.00 Registration and Coffee
Page 13: Detailed Programme - Thursday 6 Jan
Page 17 and 18: Foyer 08.00 Registration and Coffee
Page 19 and 20: Detailed Programme - Friday 7 Janua
Page 21 and 22: Acknowledgments (Trade Exhibition)
Page 23 and 24: P1 The Retention and Storage of Pos
Page 25 and 26: P9 Audit of B3 Breast Core Biopsies
Page 27 and 28: P17 Potential Roles of Corticotropi
Page 29 and 30: P25 MGMT Methylation is Strongly As
Page 31 and 32: P33 ‘Brainless’ Autopsy - an Au
Page 33 and 34: P41 Epithelioid Angiosarcoma Involv
Page 35 and 36: P49 An Analysis of Microsatellite I
Page 37 and 38: P57 Collision Tumour of the Sigmoid
Page 39 and 40: P65 Palatal Malignant Melanoma in a
Page 41 and 42: P73 Skp2 Expression in Diffuse Larg
Page 43 and 44: P81 Desmoplastic Small Round Cell T
Page 45 and 46: P89 A Generic Self-Learning Agent-B
Page 47: Presenter’s Index A Abbasi, S....

Winter Meeting 2011 - The Pathological Society of Great Britain ...

Create successful ePaper yourself

Delete template?

Save as template?